Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Crinetics Pharmaceuticals, Inc. (CRNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 Development of CRN04777 Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO – August 8, 2023 – Crinetics Pharmaceuticals, Inc."
05/04/2023 8-K Quarterly results
03/13/2023 8-K Other Events  Interactive Data
02/28/2023 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Paltusotine’s Phase 3 PATHFNDR-1study enrollment complete and topline data expected in 3Q 2023 - Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 - Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024 - Paltusotine’s Phase 2 study in carcinoid syndrome on track for data in 2H 2023 - CRN04894’s studies in Cushing’s disease and congenital adrenal hyperplasia commenced in 1Q 2023 SAN DIEGO – February 28, 2023"
01/09/2023 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enrollment Completed in Phase 3 PATHFNDR-1study Evaluating Oral Paltusotine for the Treatment of Acromegaly Topline results for PATHFNDR-1study expected in Q3 2023 SAN DIEGO – October 13, 2022 – Crinetics Pharmaceuticals, Inc."
10/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer SAN DIEGO, October 3, 2022 -- Crinetics Pharmaceuticals, Inc."
08/12/2022 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia CRN04777 and CRN04894 Phase 2 Studies Expected to Commence Following Finalization of Study Protocols with Global Regulators SAN DIEGO – August 12, 2022"
06/21/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Underwriting Agreement, by and among Crinetics Pharmaceuticals, Inc., SVB Securities LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP",
"Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering"
03/30/2022 8-K Investor presentation, Quarterly results
Docs: "CRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA Three months ended December 31, Twelve months ended December 31, STATEMENTS OF OPERATIONS DATA: 2021 2020 2021 2020 License revenues $ 1,078 $ — $ 1,078 $ — Grant revenues — — — 71 Total revenues 1,078 — 1,078 71 Operating expenses: Research and development 24,604 16,830 84,255 56,998 General and administrative 7,362 4,961 24,525 18,026 Total operating expenses 31,966 21,791 108,780 75,024 Loss from operations Total other income , net 94 150 61 1,141 Net loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted-average shares - basic and diluted 45,229 32,952 38,436 30,448 BALANCE SHEET DATA: December 31, 2021 December 31, 2020 Cash, cash equivalents and investments $ 333,707 $ 170,880 Working cap...",
"X X X X X"
03/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investors / Media: Corey Davis LifeSci Advisors, LLC [email protected] 915-2577 Aline Sherwood Scienta Communications [email protected] 238-8957"
03/01/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
01/12/2022 8-K Other Events  Interactive Data
01/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A."
12/23/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan and Form of Stock Option Agreement thereunder"
11/08/2021 8-K Other Events  Interactive Data
11/05/2021 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update – Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts –"
10/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Underwriting Agreement, by and among Crinetics Pharmaceuticals, Inc. and SVB Leerink LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP",
"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO - October 20, 2021 - Crinetics Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, ...",
"Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock SAN DIEGO - October 21, 2021 - Crinetics Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,576,000 shares of its common stock at a price to the public of $19.80 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $150.0 million. In addition, Crinetics has granted the underwriters a 30-day opt..."
10/20/2021 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/18/2021 8-K Other Events  Interactive Data
09/27/2021 8-K Quarterly results
09/15/2021 8-K Quarterly results
09/02/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
07/29/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Stock Purchase Agreement, by and among the Company and the Purchaser named therein",
"Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners"
06/28/2021 8-K Quarterly results
06/23/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy